SecurityAKCA / Akcea Therapeutics Inc. (00972L107)
President & CEOSoteropoulos Paula
Institutional Owners61
Institutional Shares20,528,256 - 23.98%
Common Shares Outstanding85,593,246 shares (as of 2018-03-31)
Institutional Value$ 742,814,000 USD

Institutional Stock Ownership and Shareholders()

AKCA / Akcea Therapeutics Inc. Institutional Ownership

Akcea Therapeutics Inc. (NASDAQ:AKCA) has 61 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20,528,256 shares. Largest shareholders include FMR LLC / Fidelity, Wellington Management Group LLP, Bb Biotech Ag, BlackRock Inc., Vanguard Group Inc, State Street Corp, Geode Capital Management, Llc, Altrinsic Global Advisors Llc, Eventide Asset Management, Llc, and Northern Trust Corp.
Akcea Therapeutics Inc. (NASDAQ:AKCA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/akca"><img src="https://images.fintel.io/us-akca-so.png" alt="AKCA / Akcea Therapeutics Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR BARCLAYS PLC 2,378 11,312 375.69 41 290 607.32
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 3,873 1,595 -58.82 67 41 -38.81
2018-05-11 13F-HR Cutler Group LP 127 3
2018-02-09 13F-HR RidgeWorth Capital Management LLC 18,071 314
2018-05-15 13F-HR A.R.T. Advisors, LLC 13,800 0 -100.00 239 0 -100.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 12,104 310
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 46,950 48,808 3.96 815 1,250 53.37
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 67,718 76,142 12.44 1,176 1,950 65.82
2018-05-15 13F-HR Cubist Systematic Strategies, LLC 0 7,843 0 201
2018-05-02 13F-HR RHUMBLINE ADVISERS 11,369 13,064 14.91 197 335 70.05
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 2 59 2,850.00 0 1
2018-05-11 13F-HR Cutler Group LP Put 800 1
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 20,700 530
2018-05-14 13F-HR VIRTUS ETF ADVISERS LLC 18,071 39,351 117.76 314 1,008 221.02
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 23,800 23,179 -2.61 413 594 43.83
2018-05-14 13F-HR ProShare Advisors LLC 38,076 32,725 -14.05 661 838 26.78
2018-04-18 13F-HR Sonora Investment Management, LLC 50 50 0.00 868 1,281 47.58
2018-05-15 13F-HR Metlife Investment Advisors, Llc 11,462 7,356 -35.82 199 188 -5.53
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 13,238 13,015 -1.68 230 333 44.78
2018-05-11 13F-HR SEI INVESTMENTS CO 8 8 0.00 0 0
2018-05-10 13F-HR JP Morgan Chase & Co 8,667 4,735 -45.37 150 121 -19.33
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 25,209 14,800 -41.29 438 379 -13.47
2018-05-15 13F-HR VANGUARD GROUP INC 1,180,095 1,123,758 -4.77 20,487 28,779 40.47
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 34,463 43,777 27.03 598 1,121 87.46
2018-05-03 13F-HR SG Americas Securities, LLC 6,951 0 -100.00 121 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 34,624 16,289 -52.95 600 416 -30.67
2018-05-17 13F-HR/A EVENTIDE ASSET MANAGEMENT, LLC 420,000 175,000 -58.33 7,291 4,482 -38.53
2018-05-09 13F-HR Candriam Luxembourg S.C.A. 114,571 0 -100.00 1,990 0 -100.00
2018-05-15 13F-HR STATE STREET CORP 256,624 260,309 1.44 4,458 6,664 49.48
2018-05-11 13F-HR CITIGROUP INC 129 125 -3.10 2 3 50.00
2018-05-02 13F-HR Daiwa Securities Group Inc. 368 9
2018-05-15 13F-HR JANE STREET GROUP, LLC 20,456 524
2018-05-15 13F-HR CREDIT SUISSE AG/ 27,734 26,365 -4.94 482 676 40.25
2018-05-03 13F-HR Zurcher Kantonalbank (Zurich Cantonalbank) 6,500 4,300 -33.85 113 110 -2.65
2018-04-20 13F-HR STRS OHIO 4,300 4,300 0.00 74 110 48.65
2018-05-15 13F-HR Wellington Management Group LLP 2,793,822 3,384,101 21.13 48,500 86,667 78.69
2018-05-15 13F-HR QS Investors, LLC 50 50 0.00 1 1 0.00
2018-05-11 13F-HR Quantbot Technologies LP 4,089 104
2018-05-09 13F-HR Bellevue Group AG 48,799 1,250
2018-05-09 13F-HR NORTHERN TRUST CORP 168,237 170,924 1.60 2,920 4,378 49.93
2018-05-15 13F-HR Iguana Healthcare Management, LLC 100,000 0 -100.00 1,736 0 -100.00
2018-05-15 13F-HR UBS Group AG 262 200 -23.66 4 5 25.00
2018-05-15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 5,618 5,008 -10.86 98 128,255 130,772.45
2018-05-14 13F-HR MORGAN STANLEY 33,581 36,070 7.41 583 924 58.49
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 18,900 25,600 35.45 328 656 100.00
2018-05-11 13F-HR Delpha Capital Management, Llc 1,521 0 -100.00 26 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 1,826,152 1,780,363 -2.51 31,702 45,594 43.82
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 32,396 23,865 -26.33 563 611 8.53
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 20,600 528
2018-05-14 13F-HR Virtu Financial LLC 0 12,571 0 322
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 27,566 0 -100.00 496 0 -100.00
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 10,102 9,588 -5.09 175 246 40.57
2018-05-15 13F-HR ARDSLEY ADVISORY PARTNERS 15,000 0 -100.00 260 0 -100.00
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 2,062 2,062 0.00 36 53 47.22
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 149 4
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 2,268 326 -85.63 39 8 -79.49
2018-05-17 13F-HR Legal & General Group Plc 3,976 2,705 -31.97 70 69 -1.43
2018-05-14 13F-HR FMR LLC / Fidelity 9,981,244 10,008,016 0.27 173,274 256,306 47.92
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 20,600 528
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 204,540 207,139 1.27 3,550 5,304 49.41
2018-05-11 13F-HR ALTRINSIC GLOBAL ADVISORS LLC 150,000 187,800 25.20 2,604 4,810 84.72
2018-05-14 13F-HR TEACHERS ADVISORS INC 26,702 27,855 4.32 464 713 53.66
2018-05-08 13F-HR BB BIOTECH AG 1,248,650 2,389,571 91.37 21,677 61,197 182.31
2018-05-14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 66,680 0 -100.00 1,158 0 -100.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 1,800 0 -100.00 31 0 -100.00
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 1,275 1,275 0.00 22 33 50.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 17,900 458
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 3,600 92
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 11,996 6,878 -42.66 208 176 -15.38
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 3,373 3,433 1.78 58,555 87,919 50.15
2018-05-04 13F-HR Swiss National Bank 28,300 28,300 0.00 491 725 47.66
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 97,144 2,488
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 25,300 648
2018-05-14 13F-HR GRANAHAN INVESTMENT MANAGEMENT INC/MA 194,376 0 -100.00 3,374 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 64,036 64,984 1.48 1,112 1,665 49.73

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

9h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Eidos Therapeutics IPO: Phase 2 Results In 2018, And 30% In Cash Per Share

2018-06-12 seekingalpha
Investors only checking the balance sheet will not notice $48 million from the conversion of convertible preferred stock. (44-1)

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

2018-06-08 seekingalpha
Akcea witnessed the substantial insider purchases, and thus signifies strong corporate prospects. The company in-licensed a stellar molecule (Inotersen) from Ionis for development. (22-1)

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested. (627-6)

Prothena Still Remains A Great Short Opportunity After Workforce Reduction

2018-05-29 seekingalpha
PRX002 is being explored to treat patients with Parkinson's disease but that candidate is not expected to readout results until 2020/2021. (5-0)

Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way?

2018-05-14 seekingalpha
Ionis and Akcea obtain a favorable outcome from an advisory panel with a vote of 12 "for" and 8 "against" approval of volanesorsen. (5-0)

CUSIP: 00972L107